Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.
Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphom
Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that
Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with a deal to license a drug for B-cell cancers developed by Xencor.
With the ink barely dry on the FDA's approval of Johnson & Johnson's Rybrevant, its first bispecific antibody for cancer, the drugmaker is already showcasing others in its pipeline.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
